Trials / Completed
CompletedNCT00031967
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
A Randomized Phase II Study of A.M. and P.M. Melatonin for Brain Metastasis in RPA Class II Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Radiation Therapy Oncology Group · Network
- Sex
- All
- Age
- 0 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy. PURPOSE: Randomized phase II trial to determine the effectiveness of combining melatonin with radiation therapy in treating patients who have brain metastases.
Detailed description
OBJECTIVES: * Determine the effect of melatonin, used as radiosensitization/radioprotection, on overall survival and clinical deterioration in patients with brain metastases who are undergoing radiotherapy. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to planned chemotherapy after whole brain irradiation (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo whole brain irradiation once daily 5 days a week for 2 weeks. Patients receive oral melatonin once daily every morning. * Arm II: Patients undergo whole brain irradiation as in arm I. Patients receive oral melatonin once daily every evening. All patients continue on melatonin for 6 months in the absence of disease progression or unacceptable toxicity. Patients are followed at months 6 and 12 from start of radiotherapy and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 128 patients (64 per treatment arm) will be accrued for this study within 5 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | therapeutic melatonin | |
| RADIATION | radiation therapy |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2004-03-01
- First posted
- 2003-01-27
- Last updated
- 2020-10-22
Locations
234 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00031967. Inclusion in this directory is not an endorsement.